Co-prescription patterns of cardiovascular preventive treatments: A cross-sectional study in the Aragon worker' health study (Spain)
Resumen: Objectives: To identify cardiovascular disease (CVD) preventive treatments combinations, among them and with other drugs, and to determine their prevalence in a cohort of Spanish workers.
Design: Cross-sectional study. Setting Aragon Workers'' Health Study (AWHS) cohort in Spain. Participants 5577 workers belonging to AWHS cohort. From these subjects, we selected those that had, at least, three prescriptions of the same therapeutic subgroup in 2014 (n=4605). Primary and secondary outcome measures Drug consumption was obtained from the Aragon Pharmaceutical Consumption Registry (Farmasalud). In order to know treatment utilisation, prevalence analyses were conducted. Frequent item set mining techniques were applied to identify drugs co-prescription patterns. All the results were stratified by sex and age.
Results: 42.3% of men and 18.8% of women in the cohort received, at least, three prescriptions of a CVD preventive treatment in 2014. The most prescribed CVD treatment were antihypertensives (men: 28.2%, women 9.2%). The most frequent association observed among CVD preventive treatment was agents acting on the renin-angiotensin system and lipid-lowering drugs (5.1% of treated subjects). Co-prescription increased with age, especially after 50 years old, both in frequency and number of associations, and was higher in men. Regarding the association between CVD preventive treatments and other drugs, the most frequent pattern observed was lipid-lowering drugs and drugs used for acid related disorders (4.2% of treated subjects).
Conclusions: There is an important number of co-prescription patterns that involve CVD preventive treatments. These patterns increase with age and are more frequent in men. Mining techniques are a useful tool to identify pharmacological patterns that are not evident in the individual clinical practice, in order to improve drug prescription appropriateness.

Idioma: Inglés
DOI: 10.1136/bmjopen-2018-023571
Año: 2019
Publicado en: BMJ Open 9, 4 (2019), e023571 [8 pp]
ISSN: 2044-6055

Factor impacto JCR: 2.496 (2019)
Categ. JCR: MEDICINE, GENERAL & INTERNAL rank: 52 / 165 = 0.315 (2019) - Q2 - T1
Factor impacto SCIMAGO: 1.247 - Medicine (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B02-17R
Financiación: info:eu-repo/grantAgreement/ES/DGA/B12-17R
Financiación: info:eu-repo/grantAgreement/ES/DGA-GRISSA/B09-17R
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI17-01704
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI13-01668
Tipo y forma: Article (Published version)
Área (Departamento): Área Medic.Prevent.Salud Públ. (Dpto. Microb.Med.Pr.,Sal.Públ.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.


Exportado de SIDERAL (2022-09-08-11:53:49)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2019-05-09, last modified 2022-09-08


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)